Katherine Widdowson

Katherine leads our medicinal chemistry efforts. Before joining Equator, she spent 27 years at GSK where she led the medicinal chemistry group in the Antibacterial Discovery Performance Unit. Her group advanced to clinical trials four novel mechanism anti-bacterials – PDF, DNA gyrase, LRS (Anacor), and catechol cephalosporins (Shionogi). Previously Katherine led the medicinal chemistry group in Chronic Obstructive Pulmonary Disease (COPD) to develop a portfolio of muscarinic receptor antagonists. These include umeclidinium bromide, which is currently marketed for COPD. Dr. Widdowson obtained her Ph.D. in Chemistry from the California Institute of Technology.